Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-
rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug …

Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, and …

Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …

The concept that inflammation participates pivotally in the pathogenesis of atherosclerosis
and its complications has gained considerable attention, but has not yet entered clinical …

There are currently more than 1000 prescription medications available for use in the United
States and more than 100,000 over-the-counter herbal and dietary supplements (HDS) …

Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Objective To develop initial American College of Rheumatology (ACR) guidelines on the
use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease …

Methotrexate (MTX) is significantly more effective than and has a considerable advantage
over placebo in patients with severe and persistent rheumatoid arthritis (RA). The drug is …